Are you interested in exploring collaboration possibilities?
Enter your information in the form and a representative will contact you shortly.
Treprostinil Reduces Fibrosis Biomarkers in the Scar-in-a-Jar Model Using a Fibrotic Cocktail
September 7, 2024
Treprostinil reduces clinically relevant fibrosis biomarkers in the Scar-in-a-Jar model using a fibrotic cocktail
Introduction
The activation of fibroblasts and the subsequent deposition of extracellular matrix (ECM) play a pivotal role in the development of interstitial lung disease (ILD), making it crucial for novel anti-fibrotic drugs.
In this study, we investigated the effects of a fibrotic cocktail (FC) that consists of eight pro-fibrotic and pro-inflammatory cytokines and one growth factor in the Scar-in-a-Jar fibroblast model, thereby mimicking the complex microenvironment associated with fibrotic ILDs.
Poster
Conclusion
The FC effectively stimulated fibrogenesis in the Scar-in-a-Jar in-vitro model, leading to elevated
levels of the fibrosis biomarkers nordicPROC3 TM, nordicPRO-C6™ and nordicFBN-CT™. Treprostinil significantly inhibited fibrogenesis and collagen deposition quantified by ELISA. In conclusion, the Scar-in-a-Jar model is a useful tool for screening novel anti-fibrotic drugs.
